Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

octapharma ab - anti-d immunglobulin, humant - pulver och vätska till injektionsvätska, lösning - 1250 ie - anti-d immunglobulin, humant 1250 ie aktiv substans - immunglobulin mot rh-immunisering

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

octapharma ab - anti-d immunglobulin, humant - injektionsvätska, lösning i förfylld spruta - 625 ie/ml - anti-d immunglobulin, humant 625 ie aktiv substans - immunglobulin mot rh-immunisering

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

octapharma ab - anti-hepatit b-immunglobulin, humant - injektionsvätska, lösning - 200 ie/ml - anti-hepatit b-immunglobulin, humant 200 ie aktiv substans - immunglobulin mot hepatit b

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

omrix biopharmaceuticals sa - anti-hepatit b-immunglobulin, humant - infusionsvätska, lösning - 50 ie/ml - anti-hepatit b-immunglobulin, humant 50 ie aktiv substans - immunglobulin mot hepatit b

Europese Unie - Zweeds - EMA (European Medicines Agency)

biokema anstalt - bovint koncentrerat laktoserum innehållande specifika immunoglobuliner g mot e. coli f5 (k99) adhesin - immunologiska medel för bovidae - kalvar, neonatal under 12 år - reduktion av mortalitet orsakad av enterotoxicos associerad med e. coli f5 (k99) adhesin under de första dagarna av livet som ett komplement till kolostrum från dammen.

Zweden - Zweeds - Läkemedelsverket (Medical Products Agency)

biokema anstalt - immunglobulin g, bovint, anti immunglobulin g, bovint, anti-escherichia coli f5(k99)-adhesin, från kolostrum - oral lösning - nöt

Europese Unie - Zweeds - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpura, trombocytopenisk, idiopatisk - hemostatika - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunoglobuliner). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroider, immunoglobuliner).

Europese Unie - Zweeds - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 och 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 och 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Europese Unie - Zweeds - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocytopeni - hemostatika - doptelet är indicerat för behandling av svår trombocytopeni hos vuxna patienter med kronisk leversjukdom som är planerade att genomgå ett ingrepp. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunoglobuliner).

Europese Unie - Zweeds - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, tarm -, antiinflammatoriska / antiinfective agenter - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.